Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 11/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 5/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 5/20 | 1.00 |
| ▸ | MAPT | P10636 | 6/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.67 |
| ▸ | THRB | P10828 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17653389 | 0.87 | GAA (1.00) | GAAL3MBTL1MEN1KMT2AMAPT | |
| SCHEMBL17653356 | 0.86 | GAA (0.83) | GAAL3MBTL1MEN1KMT2AMAPT | |
| SCHEMBL17653306 | 0.83 | GAA (0.82) | GAAL3MBTL1MEN1KMT2AMAPT | |
| SCHEMBL17653355 | 0.81 | GAA (0.68) | GAAL3MBTL1MEN1KMT2AMAPT | |
| SCHEMBL18669002 | 0.76 | GAA (0.60) | GAAL3MBTL1MEN1KMT2AMAPT | |
| SCHEMBL17653370 | 0.75 | GAA (0.69) | GAAL3MBTL1MEN1KMT2AMAPT | |
| SCHEMBL17653325 | 0.73 | GAA (0.58) | GAAL3MBTL1MEN1KMT2AMAPT | |
| SCHEMBL28725415 | 0.71 | MEN1 (0.55) | GAAL3MBTL1MEN1KMT2AMAPT | |
| SCHEMBL22190817 | 0.70 | GAA (0.54) | GAAL3MBTL1MEN1KMT2AMAPT | |
| SCHEMBL22191473 | 0.70 | GAA (0.53) | GAAL3MBTL1MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10112895-B2 | Antivirals against molluscum contagiosum virus | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2018-10-30 | — | — | US | claimed |
| EP-3200778-A1 | ANTIVIRALS AGAINST MOLLUSCUM CONTAGIOSUM VIRUS | The Trustees Of The University Of Pennsylvania (US) | 2017-08-09 | — | — | EP | claimed |
| US-20170217882-A1 | ANTIVIRALS AGAINST MOLLUSCUM CONTAGIOSUM VIRUS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2017-08-03 | — | — | US | claimed |
| WO-2016053893-A1 | ANTIVIRALS AGAINST MOLLUSCUM CONTAGIOSUM VIRUS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2016-04-07 | — | — | WO | claimed |
| US-10112895-B2 | Antivirals against molluscum contagiosum virus | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2018-10-30 | — | — | US | disclosed |
| US-20170217882-A1 | ANTIVIRALS AGAINST MOLLUSCUM CONTAGIOSUM VIRUS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2017-08-03 | — | — | US | disclosed |
| US-20170217882-A1 | ANTIVIRALS AGAINST MOLLUSCUM CONTAGIOSUM VIRUS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2017-08-03 | — | — | US | disclosed |
| US-20170217882-A1 | ANTIVIRALS AGAINST MOLLUSCUM CONTAGIOSUM VIRUS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2017-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10112895-B2 | Antivirals against molluscum contagiosum virus | EIF2AK2, IRF3, ZC3HAV1 | GAA 67/4885L3MBTL1 2533/4885MEN1 3322/4885 |
| US-20170217882-A1 | ANTIVIRALS AGAINST MOLLUSCUM CONTAGIOSUM VIRUS | EIF2AK2, IRF3, ZC3HAV1 | GAA 67/4885L3MBTL1 2533/4885MEN1 3322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.